In The News

What the U.S. Federal Government Might Learn from States About Regulating Drug Pricing

Practices: Health Care, Life Sciences, Drug Pricing & Price Reporting, Digital Health, Managed Care

Capital Insights.

While federal drug pricing reforms have taken a back seat to the coronavirus pandemic during President Biden's first 100 days, interest in the topic remains strong among federal policymakers, state governments and voters.

In a Law360 article, health care partner Margaux Hall and associates Scott Falin (both of Washington, D.C.) and Dustin Schaefer (Boston) explore state legislative efforts in drug pricing and reporting and consider how the Biden administration and Congress might learn from states' experiences as the federal government crafts its own drug pricing policy for the next four years.

Cookie Settings